Foundation Medicine , based in Cambridge , MA , has announced the commercial launch of FoundationACT ( Assay for Circulating Tumor DNA ) , a tissue - based genomic profiling assay for cancer patients who are not candidates for a tissue - based biopsy . The company claims that it has overcome many of the clinical challenges of other liquid biopsy technologies and allows the company to be the " go - to resource for a complete , end - to - end suite of comprehensive molecular imaging solutions . "
Foundation Medicine, based in Cambridge, MA, has announced the commercial launch of FoundationACT (Assay for Circulating Tumor DNA), a blood-based genomic profiling assay for cancer patients who are not candidates for a tissue-based biopsy. The company claims that it has overcome many of the clinical limitations of other liquid biopsy tests and allows the company to be the "go-to resource for a complete, end-to-end offering of comprehensive molecular information solutions."